-
公开(公告)号：US11926655B2
公开(公告)日：2024-03-12
申请号：US16631394
申请日：2018-07-17
Applicant: Daiichi Sankyo Company, Limited
Inventor： Hidenori Yano , Daisuke Nishimiya , Ryuji Hashimoto , Yoichi Niitsu
CPC classification number: C07K14/8135 , A61K47/62 , A61K47/68 , C07K14/001 , C12P21/02 , G01N33/68 , A61K38/00
Abstract: The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.
-
公开(公告)号：US20240360200A1
公开(公告)日：2024-10-31
申请号：US18663615
申请日：2024-05-14
Applicant: DAIICHI SANKYO COMPANY, LIMITED
Inventor： Daisuke Nishimiya , Hidenori Yano , Hidenori Takahashi , Shinji Yamaguchi , Shiho Ofuchi
CPC classification number: C07K14/81 , A61K38/55 , A61K38/57 , C07K14/811 , C07K14/8135 , A61K38/00 , C07K2319/30
Abstract: SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.
-
公开(公告)号：US20210340221A1
公开(公告)日：2021-11-04
申请号：US17326280
申请日：2021-05-20
Applicant: DAIICHI SANKYO COMPANY, LIMITED
Inventor： Daisuke Nishimiya , Hidenori Yano , Hidenori Takahashi , Shinji Yamaguchi , Shiho Ofuchi
Abstract: SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.
-
公开(公告)号：US20210032313A1
公开(公告)日：2021-02-04
申请号：US17064543
申请日：2020-10-06
Applicant: DAIICHI SANKYO COMPANY, LIMITED
Inventor： Daisuke Nishimiya , Hidenori Yano , Hidenori Takahashi , Shinji Yamaguchi , Shiho Ofuchi
IPC: C07K14/81
Abstract: Provided is a novel peptide. The peptide contains the amino acid sequence set forth in SEQ ID NO: 61 and inhibits a protease.
-
公开(公告)号：US12043658B2
公开(公告)日：2024-07-23
申请号：US18057480
申请日：2022-11-21
Applicant: Daiichi Sankyo Company, Limited
Inventor： Hidenori Yano , Daisuke Nishimiya , Ryuji Hashimoto , Yoichi Niitsu
CPC classification number: C07K14/8135 , A61K47/62 , A61K47/68 , C07K14/001 , C12P21/02 , G01N33/68 , A61K38/00
Abstract: The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.
-
Patent Agency Ranking
公开(公告)号：US20220306725A1
公开(公告)日：2022-09-29
申请号：US17707857
申请日：2022-03-29
Applicant: DAIICHI SANKYO COMPANY, LIMITED
Inventor： Daisuke Nishimiya , Hidenori Yano , Hidenori Takahashi , Shinji Yamaguchi , Shiho Ofuchi
Abstract: SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.
-
公开(公告)号：US11292828B2
公开(公告)日：2022-04-05
申请号：US17326280
申请日：2021-05-20
Applicant: DAIICHI SANKYO COMPANY, LIMITED
Inventor： Daisuke Nishimiya , Hidenori Yano , Hidenori Takahashi , Shinji Yamaguchi , Shiho Ofuchi
Abstract: SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.
-
公开(公告)号：US12024547B2
公开(公告)日：2024-07-02
申请号：US17707857
申请日：2022-03-29
Applicant: DAIICHI SANKYO COMPANY, LIMITED
Inventor： Daisuke Nishimiya , Hidenori Yano , Hidenori Takahashi , Shinji Yamaguchi , Shiho Ofuchi
CPC classification number: C07K14/81 , A61K38/55 , A61K38/57 , C07K14/811 , C07K14/8135 , A61K38/00 , C07K2319/30
Abstract: SPINK2 mutant peptide conjugates are provided that inhibit KLK5. The KLK5 inhibitory peptide conjugates are Fc fusion peptides in which, in certain embodiments, the Fc region of the fusion peptides are the Fc region of human IgG1 or a fragment thereof. The KLK5 inhibitory peptide conjugates include an amino acid sequence of one of SEQ ID NOs: 34, 36, 38, 40, 42, 44, 46, 48, 96, 50, 52, 54, 56, 58, or 60. Pharmaceutical compositions that include the KLK5 inhibitory peptide conjugates useful for treating KLK5-related diseases are also provided.
-
公开(公告)号：US20230203132A1
公开(公告)日：2023-06-29
申请号：US18057480
申请日：2022-11-21
Applicant: Daiichi Sankyo Company, Limited
Inventor： Hidenori Yano , Daisuke Nishimiya , Ryuji Hashimoto , Yoichi Niitsu
CPC classification number: C07K14/8135 , A61K47/62 , A61K47/68 , C07K14/001 , C12P21/02 , G01N33/68 , A61K38/00
Abstract: The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.
-
公开(公告)号：US20220002385A1
公开(公告)日：2022-01-06
申请号：US17291956
申请日：2019-11-06
Applicant: Daiichi Sankyo Company, Limited
Inventor： Daisuke Nishimiya , Hidenori Yano
IPC: C07K14/81
Abstract: A method for improving blood kinetics of a peptide is provided. The method for improving blood kinetics of a peptide includes a step of preparing a peptide having a modified amino acid sequence.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.017 seconds)
